文献速递胸部病理细胞病理与分子病理

法国非小细胞肺癌预测性分子病理的过去、现在与展望

Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives.
PubMed 文献 · Cancer Cytopathol · 2020-01-01

本文综述法国非小细胞肺癌(NSCLC)分子病理检测的发展历程:2007年法国国家癌症研究所(INCa)建立28家医院分子遗传中心(MGCC),从靶向PCR检测少数基因,到2015年引入NGS技术,并建立创新检测的财务报销制度;2018年实施「法国2025基因组医学」战略计划,推动系统化测序并将大panel检测集中至少数分子遗传中心。

要点

  • 2007年INCa建立28家MGCC,启动NSCLC分子检测网络。
  • 2015年MGCC获专项预算发展NGS技术,检测基因数增加。
  • 2018年「法国2025基因组医学」计划推动系统化测序与检测集中化。

核心结论

  • 法国通过国家网络和专项预算逐步建立并扩展NSCLC分子病理检测体系,并正向系统化测序和集中化检测演进。

研究设计与样本

  • 本文为综述,描述法国NSCLC分子病理检测实施各阶段的演变。

主要发现

  • 2007年INCa建立28家医院MGCC,实验室最初用靶向PCR检测少数基因,后增加检测基因数。
  • 2015年MGCC获INCa额外专项预算发展NGS技术。
  • INCa对基于基因的PCR检测或NGS检测给予检测费用报销,但实验室认为报销仅部分且使用复杂。
  • 2018年实施「法国2025基因组医学」战略计划,将系统化测序引入医疗路径和肿瘤实践,大panel检测应集中至少数分子遗传中心。

临床怎么用

  • 法国公私实验室均可获得肿瘤分子生物学检测资助,NSCLC患者可接受PCR或NGS检测。
  • 大型分子检测panel应集中至少数分子遗传中心开展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The advent of molecular targets for novel therapeutics in oncology, notably for non-small cell lung carcinoma (NSCLC), led the French National Cancer Institute (INCa) to establish a national network of 28 hospital Molecular Genetics Centers for Cancer (MGCC) in 2007. In each University in France, laboratories were established to develop molecular biology testing to evaluate a few genomic alterations, initially a selection of genes, by using specific targeted polymerase chain reaction (PCR) assays. In a second phase, the number of studied genes was increased. In 2015, the MGCC benefited from an additional dedicated budget from the INCa to develop next-generation sequencing (NGS) technology. In the meantime, a new financial regulation for innovative testing has been established for the acts out of nomenclature. Consequently, all private and public laboratories in France have access to funding for molecular biology testing in oncology. The gene-based PCR assays or NGS tests have benefitted from reimbursement of cost testing by the INCa. Today, the laboratories consider this reimbursement to be only partial, and its use to be complex. In 2018, a strategic plan for medical genomic analyses (France Médecine Génomique 2025) was implemented to introduce more systematic sequencing into the health care pathway and oncology practice. The large panel of molecular tests should be centralized to a limited number of molecular genetic centers. This review describes the evolution of the different stages of implementation of molecular pathology testing for NSCLC patients over the last few years in France.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Hofman P, Rouleau E, Sabourin JC, et al. Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives. Cancer Cytopathol. 2020. PMID: 32885912. doi:10.1002/cncy.22318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。